Childhood-Onset Schizophrenia

Kumra, Sanjiv; Frazier, Jean A.; Jacobsen, Leslie K.; McKenna, K.F.; Gordon, Charles T.; Lenane, Marge; Hamburger, Susan; Smith, Aleah; Albus, Kathleen E.; Alaghband-Rad, Javad; Rapoport, Judith L.

doi:10.1001/archpsyc.1996.01830120020005

Cited by 357 publications

(31 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The research question was raised because early onset of schizophrenia under age of 18 years was noticed in 50% of patients and is associated with increased severity and antipsychotic drug resistance (Kumra and Charles Schulz, 2008). Previously Kumra et al (1996) demonstrated that clozapine was superior to haloperidol. Because olanzapine has been shown to have superiority to other agents in adults, the current study was thus carried out.…”

Section: Iv: Treatmentmentioning

confidence: 99%

The 2nd Schizophrenia International Research Society Conference, 10–14 April 2010, Florence, Italy: Summaries of oral sessions

Baharnoori

Bartholomeusz

Boucher³

et al. 2010

Schizophrenia Research

View full text Add to dashboard Cite

The 2nd Schizophrenia International Research Society Conference, was held in Florence, Italy, April 10–15, 2010. Student travel awardees served as rapporteurs of each oral session and focused their summaries on the most significant findings that emerged from each session and the discussions that followed. The following report is a composite of these reviews. It is hoped that it will provide an overview for those who were present, but could not participate in all sessions, and those who did not have the opportunity to attend, but who would be interested in an update on current investigations ongoing in the field of schizophrenia research.

show abstract

Section: Iv: Treatmentmentioning

confidence: 99%

The 2nd Schizophrenia International Research Society Conference, 10–14 April 2010, Florence, Italy: Summaries of oral sessions

Baharnoori

Bartholomeusz

Boucher³

et al. 2010

Schizophrenia Research

View full text Add to dashboard Cite

show abstract

“…In effect, several lines of evidence have been put forward: e.g., lysergic acid (LSD), an agonist of serotonin receptors, has psychotomimetic effects [Serretti et al, 1999a], and atypical neuroleptics such as clozapine and risperidone, which strongly bind to 5-HT receptors, show striking superiority over D2 antagonists (i.e., typical neuroleptics) for the treatment of schizophrenia [Kumra et al, 1996]. Tryptophan hydroxylase (EC1.14.16.4, accession no.…”

Section: Introductionmentioning

confidence: 99%

Childhood‐onset schizophrenia and tryptophan hydroxylase gene polymorphism

Sekizawa

Iwata

Nakamura

et al. 2004

American J of Med Genetics Pt B

View full text Add to dashboard Cite

We explored the relationship between the tryptophan hydroxylase gene polymorphism and susceptibility to childhood-onset schizophrenia in a Japanese sample. Subjects were 51 Japanese patients who met DSM-IV criteria for schizophrenia before age 16 and 148 Japanese healthy controls. DNA was extracted from whole blood and genotyping was performed by PCR-RFLP using Nhe I. The frequency of the A allele was relatively higher in patients with childhood-onset schizophrenia than in controls (odds ratio, OR = 1.47, 95% CI = 0.97-2.37, P = 0.097). There was a nearly doubling of the risk for childhood-onset schizophrenia associated with the AA genotype compared to other genotype groups; OR = 1.97, 95% CI = 0.91-4.22, P = 0.058.

show abstract

“…This would not only contravene the National Institute for Clinical Excellence guidance on atypical antipsychotics, which states that 'in individuals with evidence of treatment resistant schizophrenia clozapine should be introduced at the earliest opportunity' (National Institute for Clinical Excellence, 2002), but it would also deprive patients of a potentially unique and effective treatment. Some studies in fact suggest that its use might be worthwhile and beneficial in children and young people (Kumra et al, 1996;MacEwan & Morton, 1996;Turetz et al, 1997).…”

mentioning

confidence: 99%

Clozapine prescribing in adolescent psychiatry: survey of prescribing practice in in-patient units

Cirulli¹

2005

Psychiatr. bull.

View full text Add to dashboard Cite

Aims and MethodClozapine is an effective drug in treatment-resistant schizophrenia, but it seems to be prescribed for few patients under the age of 18 years. This study reports a survey of consultant psychiatrists working in adolescent units in the UK, looking at their use of clozapine and experience with it.ResultsOut of 83 clinicians, 59 responded (71%). More than 40% of respondents do not use clozapine, and those who do may not always be following best practice recommendations. Reasons for not using clozapine, beliefs about its effectiveness and problems encountered in its use are described.Clinical ImplicationsClozapine may not always be made available to young people with treatment-resistant schizophrenia. There is a need for more education, guidance and debate on clozapine use in child and adolescent psychiatry.

show abstract

Childhood-Onset Schizophrenia

Abstract: Clozapine has striking superiority for positive and negative symptoms in treatment-refractory childhood-onset schizophrenia. However, due to possibly increased toxic effects in this pediatric population, close monitoring for adverse events is essential.

Cited by 357 publications

References 49 publications

The 2nd Schizophrenia International Research Society Conference, 10–14 April 2010, Florence, Italy: Summaries of oral sessions

The 2nd Schizophrenia International Research Society Conference, 10–14 April 2010, Florence, Italy: Summaries of oral sessions

Childhood‐onset schizophrenia and tryptophan hydroxylase gene polymorphism

Clozapine prescribing in adolescent psychiatry: survey of prescribing practice in in-patient units

Contact Info

Product

Resources

About